Literature DB >> 9790194

Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor.

Y Kato1, R I Tapping, S Huang, M H Watson, R J Ulevitch, J D Lee.   

Abstract

Epidermal growth factor (EGF) induces cell proliferation in a variety of cell types by binding to a prototype transmembrane tyrosine kinase receptor. Ligation of this receptor by EGF activates Erk1 and Erk2, members of the mitogen-activated protein (MAP) kinase family, through a Ras-dependent signal transduction pathway. Despite our detailed understanding of these events, the exact mechanism by which EGF causes cells to proliferate is unclear. Big MAP kinase (Bmk1), also known as Erk5, is a member of the MAP kinase family that is activated in cells in response to oxidative stress, hyperosmolarity and treatment with serum. Here we show that EGF is a potent activator of Bmk1. In contrast to Erk1/2, EGF-mediated activation of Bmk1 occurs independently of Ras and requires the MAP-kinase kinase Mek5. Expression of a dominant-negative form of Bmk1 blocks EGF-induced cell proliferation and prevents cells from entering the S phase of the cell cycle. These results demonstrate that Bmk1 is part of a distinct MAP-kinase signalling pathway that is required for EGF-induced cell proliferation and progression through the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790194     DOI: 10.1038/27234

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  126 in total

1.  MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling.

Authors:  M T Diaz-Meco; J Moscat
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.

Authors:  G Pearson; J M English; M A White; M H Cobb
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

3.  Role of MEKK2-MEK5 in the regulation of TNF-alpha gene expression and MEKK2-MKK7 in the activation of c-Jun N-terminal kinase in mast cells.

Authors:  K Chayama; P J Papst; T P Garrington; J C Pratt; T Ishizuka; S Webb; S Ganiatsas; L I Zon; W Sun; G L Johnson; E W Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  Expression of pref-1/dlk-1 is regulated by microRNA-143 in 3T3-L1 cells.

Authors:  Yoon-Jin Kim; Tae Sun Min; Kang-Seok Seo; Sang Hoon Kim
Journal:  Mol Biol Rep       Date:  2014-11-04       Impact factor: 2.316

5.  Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1.

Authors:  Matthew S Squires; Paula M Nixon; Simon J Cook
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

6.  The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling.

Authors:  Lei Zhang; Ole Gjoerup; Thomas M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

7.  MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src.

Authors:  Weiyong Sun; Xudong Wei; Kamala Kesavan; Timothy P Garrington; Ruihua Fan; Junjie Mei; Steven M Anderson; Erwin W Gelfand; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  Cyclic AMP selectively uncouples mitogen-activated protein kinase cascades from activating signals.

Authors:  Gray W Pearson; Svetlana Earnest; Melanie H Cobb
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Involvement of ATM/ATR-p38 MAPK cascade in MNNG induced G1-S arrest.

Authors:  Ke-Qing Zhu; Suo-Jiang Zhang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

10.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

Authors:  Masaaki Hayashi; Sung-Woo Kim; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; E Dale Abel; Brian Eliceiri; Young Yang; Richard J Ulevitch; Jiing-Dwan Lee
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.